Trial Profile
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzastaurin (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 17 Nov 2006 Status change
- 11 Oct 2006 New trial record.